title: Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?
authors.forename: Emilio Paolo
authors.initials: EP
authors.lastname: Alessandrino
authors.forename: Matteo Giovanni
authors.initials: MG
authors.lastname: Della Porta
authors.forename: Cristiana
authors.initials: C
authors.lastname: Pascutto
authors.forename: Andrea
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000601:surgery*
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine